Floatz logo

Olaparib

Thyroid Gland Carcinoma

University Medical Center GroningenSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Thyroid Gland Carcinoma cohort.

Asset / SponsorPhaseRating
Palbociclib
University Medical Center Groningen
Phase 4BB
Lenvatinib
University Medical Center Groningen
Phase 4BB
Pazopanib
University Medical Center Groningen
Phase 4B
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
Dasatinib
National Cancer Institute (NCI)
Phase 2CCC

View all 39 →

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
fallopian tube serous adenocarcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
ovarian carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →